Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) Return on Equity (2016 - 2025)

Historic Return on Equity for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to 0.24%.

  • Catalyst Pharmaceuticals' Return on Equity rose 400.0% to 0.24% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.24%, marking a year-over-year increase of 400.0%. This contributed to the annual value of 0.29% for FY2024, which is 1200.0% up from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported Return on Equity of 0.24% as of Q3 2025, which was up 400.0% from 0.25% recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Return on Equity ranged from a high of 0.41% in Q1 2021 and a low of 0.1% during Q2 2024
  • Over the past 5 years, Catalyst Pharmaceuticals' median Return on Equity value was 0.24% (recorded in 2022), while the average stood at 0.24%.
  • In the last 5 years, Catalyst Pharmaceuticals' Return on Equity plummeted by -3200bps in 2021 and then skyrocketed by 1600bps in 2025.
  • Catalyst Pharmaceuticals' Return on Equity (Quarter) stood at 0.19% in 2021, then soared by 50bps to 0.29% in 2022, then plummeted by -44bps to 0.16% in 2023, then soared by 46bps to 0.24% in 2024, then increased by 4bps to 0.24% in 2025.
  • Its Return on Equity stands at 0.24% for Q3 2025, versus 0.25% for Q2 2025 and 0.26% for Q1 2025.